Diseases of Pulmonary Vasculature
A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.
Evaluating diagnosis and treatment options for pulmonary arterial hypertension.
A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.
Exercise intolerance is a hallmark symptom of pulmonary arterial hypertension.
The diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis is evaluated.
Development of CTEPH is associated with traditional thrombotic risk factors, including thrombophilias and inflammatory processes.
Future clinical trials on pulmonary arterial hypertension should include patients from diverse racial and ethnic backgrounds.
The most common chronic respiratory morbidity affecting preterm neonates is bronchopulmonary dysplasia.
The risk of perioperative complications is increased by many factors in patients undergoing thoracic surgery.
James E. Loyd, MD, and Wendy Chung, MD, PhD, offer insight into the role of genetics in pulmonary arterial hypertension.
In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.
Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.
Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.
N-terminal-pro brain natriuretic peptide may be a useful biomarker for both mortality and respiratory exacerbations in pediatric patients with pulmonary hypertension.
Patients with pulmonary hypertension have a high risk for adverse events during and following cardiac catheterization, but high case volume may help ameliorate this risk.
Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions are inconsistent with pulmonary hypertension guidelines.
Patients with pulmonary arterial hypertension may be better identified with the use of a claims-based algorithm that includes ICD-9-CM codes, electronic medical records, and more.
Right atrium enlargement may predict the risk for supraventricular arrhythmias in patients with pulmonary arterial hypertension.
Women with pulmonary arterial hypertension may have better long-term prognoses compared with men, potentially because of improvements in right ventricular function.
A 3-month risk for a thromboembolic event was assessed using a pulmonary embolism rule-out criteria strategy and compared with a conventional strategy in patients with a low clinical probability of pulmonary embolism.
Acute pulmonary embolism may be managed in an outpatient setting when the patient has a low risk for mortality.
Hypoxemia is associated with reduced survival in patients with idiopathic or heritable pulmonary arterial hypertension.
Peak circulatory may provide reliable prognostic information in patients with idiopathic pulmonary arterial hypertension.
The 6MWT is a clinically relevant and appropriate target for patients with pulmonary arterial hypertension.
Certain risk scores may not be reliable for predicting the presence of a pulmonary embolism in pregnant or postpartum women.
Several drugs may demonstrate different safety profiles and side effects that warrant a change in treatment for individuals with pulmonary hypertension.
To minimize the "learning effect" and improve accuracy, patients with suspected pulmonary hypertension should undergo two 6-minute walk tests.
Monitoring the plasma BNP level in individuals with pulmonary arterial hypertension may aid clinicians in therapeutic decision-making and overall prediction of 5-year survival rate.
Researchers discovered an association between global pulmonary vascular remodeling and pulmonary hypertension in patients with heart failure.
In a postmarketing surveillance study, ambrisentan demonstrated tolerability and potential effectiveness for pulmonary arterial hypertension treatment.
The Cardiology Advisor Articles
- The Mounting Evidence Against Electronic Cigarette Use
- Entresto Significantly Improves Physical, Social Activity in Heart Failure Patients
- Oxygen Therapy in Acute MI Not Associated With Clinical Benefit
- Nonpsychotic Cannabinoids in Hypertension: Benefits and Harms
- ACC and AHA Release 2018 Quality Measures for Cardiac Rehabilitation